

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

NCT06769659

Status	RECRUITING
Phase	Phase 2
Sponsor	NeuroPro Therapeutics, Inc.
Enrollment	10 participants

Key Eligibility Criteria

Inclusion (10)

- Subject is capable of and provides consent/assent, and the study participant's parent/legal representative/caregiver provides signed informed consent for minor study participants, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF)
- Subject is aged 16-75 years at the time of consent/assent
- Subject is diagnosed with genetic generalized epilepsy with absence seizures (consistent with the International League Against Epilepsy (ILAE) Classification of Seizures (2017))
- Subject has electroencephalogram (EEG) evidence of bilateral synchronous generalized paroxysmal spike-wave (2.5 Hz to 6 Hz) bursts lasting 3 seconds or more at least 4 times on the screening 72-hour ambulatory EEG.
- Subject has been on a stable dose of at least one antiseizure medication (ASM) for at least 30 days. Vagal nerve stimulation at stable settings (for at least 30 days before screening), without use of the magnet, is also acceptable.

... and 5 more (see full listing online)

Exclusion (19)

- Subject has metabolic or mitochondrial encephalopathies, seizures associated with structural abnormalities, or infection-related seizures.
- Subject has a developmental epileptic encephalopathy (e.g. Lennox-Gastaut syndrome)
- Subject has a history of convulsive status epilepticus within the past year.
- Subject has a history of surgical intervention for treatment of epilepsy
- Subject has a history of nonepileptic seizures (e.g., metabolic, structural, or paroxysmal non epileptic seizures)

... and 14 more (see full listing online)

Locations (1 total)

Clinical Trials, Inc. (CTI), Little Rock, Arkansas, United States